

DR-TB Patient Treatment Log Book

Patient Name:

Patient Reg. No.:



MOH/DPPH/DNTLD/ DRTBPTTreat.LOGBOOK/002

TABLE OF CONTENTS

1. Definitions of Treatment outcomes	3
2. Pre Treatment Evaluation /Assessment	4
2.1. Vital Sign Records	4
2.2. Drug Susceptibility Test Results	4
2.3. Baseline Lab Tests/Imaging	5
2.4. Obs/Gyn	6
2.5. Review of Systems	6
2.6. Anthropometric Measurements	7
2.7. Social Status Screening	88
2.8. Disability Assessment and Rehabilitation	8
3. Contact Management	9
4. Regimen Formulation Guide	10
5. Consenting	11
6. Treatment	13
7. Adherence Counselling	14
8.Daily Observation of Drug Intake	15
9. Daily DR-TB Drug Side Effect Monitoring Form	16
10. Monitoring Quality of Care	55
10.1. Sputum Follow Up	55
10.2 Lab/Clinical Follow Up	56
10.3.Monitoring Schedule for Patients on Injectable Free Regimen	57
10.4. DR Treatment Adjustment	58
10.5. Nutritional Intervention	59
11. Clinical Notes	60
12. Monthly DR TB Clinical Review Checklist	80
13. DR TB Treatment Outcome	81
14. Post DR TB Treatment Follow Up.	82

1. DEFINITION OF TREATMENT OUTCOMES

Outcome	Definition
Cured	Treatment completed as recommended by the national policy without evidence of failure AND three or more consecutive cultures taken at least 30 days apart are negative after the intensive phase
Treatment Complete	Treatment completed as recommended by the national policy without evidence of failure BUT no record that three or more consecutive cultures taken at least 30 days apart are negative after the intensive phase
Treatment Failed	Treatment terminated or need for permanent regimen change of at least two anti-TB drugs because of: - Lack of conversion by the end of the intensive phase, or - Bacteriological reversion in the continuation phase after conversion to negative, or - Evidence of additional acquired resistance to fluoroquinolones or second-line injectable drugs, or - Adverse Drug Reactions (ADRs)
Lost to Follow Up	A patient who started treatment and interrupted for 2 consecutive months or more
Died	A patient who dies for any reason before starting or during the course of TB treatment

2. PRE TREATMENT EVALUATION /ASSESMENT

2.1. Vital Signs									
Vital Signs	Functional status:								
BP/	Able to conduct normal activity, No special care needed								
Pulse rate/ min	Unable to conduct normal activity, Some assistance needed								
TempoC	Unable to care for self, requires hospitalization								
Resp. rate/ min									
SpO2(%)									

2.2. Drug Susceptibility Test (Genotypic/Phenotypic) Results (microbiology)

Test	Diagnostic	specimen	Result (tick / indicate all applicable)							
	Sputum	Other (specify)								
Xpert RIF/UL- TRA /TrueNat (mandatory)			No MTB	MTB/Rif Sen.	MTB/Rif Res.	MTB/Rif Indeter- minate	MTB Trace	Not done		
1 st line LPA			No MTB	MTB detected	Rif Sen.()	Rif Res.()	INH Sen.()	INH Res.()		
2 nd Line LPA			No MTB	MTB detected	FQN Sen.()	FQN Res.()				
Culture			Growth	No Growth	мотт	Contaminated	Other			
DST 1 st Line R=Resistant S=Sensitive			Isoniazid	Rifampicin	Streptomycin	Ethambutol	Pyrazinamide			
DST 2 nd Line R=Resistant S=Sensitive			FQN (Lfx/Mfx)	Linezolid	Bedaquiline	Delamanid	Clofazimine	Pretomanid		
Histology (if performed indicate report/ result)										

2.3. Baseline Lab Test Results & Imaging

Baseline lab te					
Test	Date	Results		Comment	
Creatinine					
Bilirubin					
AST					
ALT					
Potassium					
Full Hemogram					
TSH					
Pregnancy test					
Magnesium					
RBS					
Albumin					
HIV test					
CD4					
Viral Load					
Other Baselin	e tests		IMAGING T	REMARKS	
Test	Date	Results	CXR	OTHERS	
ECG (QTCF)					
Audiometry(Normal/ Abnormal)					
Visual testing	Remarks				
Ishihara test					
Snellen's test					

2.4. Obstetrical and Gynecology History

2.4. Obstetricat and dynecotogy instory	
Obs/ Gyn history	
Last menstruation date//(dd/mm/yy)	
Parity Gravidity	
Contraceptive use: YES Specify	NO
2.5. Review of Systems	
Systemic examination	
Fill in the findings on systemic examination	
Lymph nodes	
Cardiovascular system	
Respiratory system	
Abdomen	
Skin	
Urogenital system	
Musculoskeletal exam	
Neurological exam	
Other	

2.5. Anthropometric Assesment

Date	Weight (kg)	Height/Length	BMI (Above 18 years) BMI for age(5-17 years) Z score(0- 59Months) (Refer to BMI charts)	Nutrition Sup- port (Specify) (Refer to key below)	Comments
		ļ			

2.6. Social Status Scree Assessed by social worker								
Family support available (
(descri be)								
Work Status:() Paid work: Indicate the work address	() Self-employed: () None paid work:(and contact person) Student/schol	ar: () Retired:() Unemployed: ()Other			
	medical insurance, monthly stipend and r							
2.7. Disability and Reha	bilitation Assesment							
Interview date:	Initial Phase:			End of treatme	ent			
Name of interviewer:	Initial Phase:			End of treatment				
Do you have difficulties	performing the following tasks:	None		Need some assistance		Cannot do		
		Intensive Phase	End of treatment	Initial phase	End of treatment	Initial Phase	End of treatment	
1. Standing/ walking for l	ong periods (e.g 30 min)							
2.Concentrating on doing	something for 10 min							
3.Washing your whole bo	dy							
4.Getting dressed								
5.Going to toilet								
6.Your day-to-day work/s	school							
Remarks:								
Referral: (for any ticks in the grey a professional)	rea please refer to rehabilitation							

3. CONTACT SCREENING AND MANAGEMENT

Contacts are defined as persons living in the same household, or spending many hours together in the same indoor living space. Screen the contacts for symptoms and obtain a chest X-Ray at baseline. Close contacts of DR TB are at high risk of DR TB. Close contacts with TB should be treated as DR TB. Refer to the DR TB guidelines. Screen contacts for symptoms every 0 months(at time of diagnosis of the index case), 3 months, 6 months, 12 months, 18 months and 24 months. If a contact is found to have TB symptoms, obtain a chest X-Ray, genexpert/TRUENAT,FL LPA, SL LPA, and culture and DST. (Document this in the clinical notes section

								1				Ι	1	
					Date/	_/		Date / /	Date / /	Date / /	Date / /	Date / /	Date / /	Date / /
No.	Name	Age	Sex	Mobile No.	Are there TB symp- toms? (Y/N)	CXR	Gen- eXpert Results	Are there TB symp- toms? (Y/N)	Out- come TB/ No TB					
					Key 1.Normal 2.Abnormal (Sugges- tive of TB) 3.Abnormal Others 4.Not done									

4. REGIMEN FORMULATION GUIDE

	Ask	Yes	No
	A1- Has the patient been previously treated for DR-TB for >1 month?		
	A2- Does the patient have extra-pulmonary disease?		
	A3- Is there any reason to suspect that the patient has or will develop intolerance to any of the 2 nd Line medicines?		
	A4- Does the patient have severe lung damage (on CXR), such as multiple bilateral cavities, extensive parenchymal damage or lung collapse?		
	A5- Is the patient pregnant?		
Α	A6- TB? Does the patient have a close contact who: a. Had XDR TB? b. Had resistance to fluoroquinolone c. Failed or is failing treatment for DR-TB? d. Died while on treatment for DR-TB?		
	If there is YES to any of the 6 questions above, the patient is eligible for individualized regimen, go to C below If NO to all the above 6 questions, the patient is eligible for standardized regimen, go to B below		
	Trace results for 2 nd Line LPA and conventional 2 nd Line DST		
В	B1- Is there resistance to any group A drugs (FQ, Bdq, Lzd)	_	
Ь	If YES to the question above the patient requires individualized regimen, go to D below If the response to question above is NO, or results unavailable, start on standard MDR regimen		
С	Trace results for 2 nd Line LPA and conventional 2 nd line DST		
С			
С	Trace results for 2 nd Line LPA and conventional 2 nd line DST C1- Is there resistance to fluoroquinolone or any other group A drugs C2- Is there any YES on the answer to Question A6 (above)		

5. CONSENT FORM

Level	Information provided	Agreement		
	Is the patient willing to receive DOTs?	Yes	No	
	Does the patient fully understand the duration of treatment?	Yes	No	
Agree between	Does the patients understand that the health care worker will maintain confidentiality?	Yes	No	
HCW and patient	Does the patient understand the consequences of stopping/refusing treatment to himself/herself?	Yes	No	
	Does the patient understand the consequences of Stopping/refusing treatmentto their close contacts and general public?	Yes	No	
	Does the patient understand that one of the consequences of Stopping/refusing treatment is involuntary isolation for the duration of treatment?	Yes	No	
Arrange	Does the patient understand the need to organize his/her priorities in order to better cope with changes and interruptions in social life	Yes	No	
with the patient	Does the patient have a treatment supporter (caregiver or family member) that will participate in the education/ counselling sessions and help in treatment management	Yes	No	
	Does the patient have daily schedule for taking his medication and treatment plan for DOT	Yes	No	
Health care workers responsi-	Have you helped the patient to evaluate the factors likely to interfere in the treatment and their solutions?	Yes	No	
bility	Will you be available for the patient to express his emotions and other psychological reactions?	Yes	No	
	Will you assist the patient to anticipate barriers to implementing treatment plan and identify strategies to overcome them?	Yes	No	
	Have you applied the PHQ9 and CAGE form to the patient?	Yes	No	
	Is there a history of mental illness or substance abuse? (If yes, refer to appropriate care providers)	Yes	No	1

Patient/Guardian, Next of Kin/Guardian and Health Care Workers Memorandum of Understanding for DR TB Treatment

I
Patient:
Sign:
Name:
Tel
Next of Kin:
Sign:
Name:
Tel
Witness (HCW):
Sign:
Name:
Reviewed:
CTLC Sign:

Tel.....

6. TREATMENT

Date treatment started	Date started (Intensive phase)		Date started (Continuation Phase)	
Short treatment regimen (>15yrs)	Drug	Dose per Day	Drug	Dose per Day
(Treatment duration 6months)	Bedaquiline			
6BPaLM	Pretomanid			
	Linezolid			
	Moxifloxacin			
	Bedaguiline		Levofloxacin	
	Linezolid	 	Cycloserine	+
<15yrs (intensive 6 months, Continua-	Levofloxacin	+	Clofazimine	1
tion 3 months)	Levonoxacin	+	Clorazimine	+
(BLLCC)to discuss	Cycloserine	+		+
(BLLCC)lo discuss	Clofazimine			
	Bedaquiline			
	Delamanid			
	Levofloxacin			
	Moxifloxacin			
	Amikacin	İ		
	Kanamycin	İ		
	Capreomycin	İ		
	Streptomycin	i	İ	i
	Clofazimine	1		†
	Ethionamide / Prothionamide			
	Cvcloserine			
	Linezolid			
	Diferenciale	+	+	+
	Rifampicin	+	+	+
	Isoniazid	+		+
	Pyrazinamide		<u> </u>	
	Ethambutol			
	PAS			
	Imipenem/Cilastatin			
	Meropenem			
	Amoxicillin/Clavulanate			
	Thiacetazone			
	Pretomanid			
	Terizidone			
Additional treatment	Cotrimoxazole		Cotrimoxazole	
	Pyridoxine		Pyridoxine	
Antiretroviral treatment				
Other medicines				
5 IIIOMIOIIIOO				

7. ADHERENCE COUNSELING

Questions	Baseline	Day 14	Day 28	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month	Month 10	Month 11	Month 12	Month 13	Month 14	Month 15	Month 16	Month 17	Month 18	Month 19	Month 20
Date																						
Agreement between HCW and patient	****Tick appr	ropriately*	***																			
Is the patient willing to receive DOTs?																						
Does the patient fully understand the duration of treatment?																						
Does the patients understand that the health care worker will retain confidentiality?																						
Does the patient understand the consequences of stopping/refusing treatment to themselves?																						
Does the patient understand the consequences of stopping/refusing treatment to their close contacts and general																						
Does the patient understand they can be put under involuntary isolation as a consequence of stopping/refusing treatment?																						
If the patient stopped/refused TB treatment in the past, what will he/she do differently this time in order to complete treatment?																						
Arrange with the patient																						
Does the patient understand the need to organise his/ her priorities in order to better cope with changes and interruptions in social life?																						
Does the patient have a treatment supporter (care- giver or family member) that would participate in the sessions and help in treatment management?																						
Does the patient have a daily schedule and treatment plan for DOT?																						
Health care workers responsibility																					,	
Have you assisted the patient to evaluate the factors likely to interfere in the treatment and their solutions?																						
Will you be available for the patient to express his emotions and other psychological reactions?																						
Will you assist the patient to anticipate causes of treatment interruption and identify strategies to overcome them?																						
Have you applied the PHQ9 form to the patient?																						
If mental or substance abuse history, have you refered to appropriate care providers?																						

Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																
Levofloxacin (Lfx)																																
Moxifloxacin (Mfx)																																
Linezolid (Lzd)																																
Pretomanid (Pmd)																																
Clofazimine (Cfz)																																
Cycloserine (Cs)																																
Delamanid (Dlm)																																
Isoniazid (Inh)																																
Rifampicin (Rif)																																
Ethambutol (Emb)																																
Pyrazinamide (Pza)																																
High Dose Isoniazid (Hh)																																
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)																																
Kanamycin (Km)																																
Amikacin (Amk)																																
Capreomycin (Cm)																																
Imipinem (Imp)	n (Imp)																															
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes						0	Dail	y Ob	serv	ed_																						
	N Not												Con	nme	nts:																	
						Χ	Dru	g no	t tak	en																						

				4ont				ear_																									Enter code fro below	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice																							Ш										
11	Vision changes																																	
12	Oedema									<u> </u>	<u> </u>	_																				<u> </u>		ļ
13	Joint pain		Щ							<u> </u>	<u> </u>	<u> </u>														\Box		Ш						<u> </u>
14	Rash																																	
15	Discoloration of skin and mucus membrane																																	
16	Depression		\square																					Щ										
	Psychosis								<u> </u>	<u> </u>	<u> </u>																							
18	Constipation		Ш		_		_	_	<u> </u>		$oxed{oxed}$		_	_										Щ		Щ		Щ						
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23									<u> </u>		<u> </u>																							
24																																		

Side effect grading		
Grade o - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	2 Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

Mandle																																Reason for missed drug
Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																
Levofloxacin (Lfx)																																
Moxifloxacin (Mfx)																																
Linezolid (Lzd)																																
Pretomanid (Pmd)																																
Clofazimine (Cfz)																																
Cycloserine (Cs)																																
Delamanid (Dlm)																																
Isoniazid (Inh)																																
Rifampicin (Rif)																																
Ethambutol (Emb)																																
Pyrazinamide (Pza)																																
High Dose Isoniazid (Hh)																																
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)																																
Kanamycin (Km)																																
Amikacin (Amk)																																
Capreomycin (Cm)																																
Imipinem (Imp)	nem (Imp)																															
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes					()	Dail	ly Ok	serv	/ed																						
					1	N	Not	Sup	ervis	sed			Con	nme	nts:																	
						X	Dru	g no	t tak	en																						

	ILI DK-IB DKO			Mont				ear_																									Enter code fro	m key
-	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
_	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																							İ										
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness				ĺ		ĺ			İ		İ	İ											İ										
9	Fever																																	
10	Jaundice																																	
11	Vision changes																																	
12	Oedema		\sqcup				<u> </u>						<u> </u>																					
13	Joint pain																																	
_	Rash					_	<u> </u>					_	<u> </u>											<u> </u>						Щ				
	Discoloration of skin and mucus membrane																																	
$\overline{}$	Depression																																	
17	Psychosis		igsquare		$oxed{oxed}$	$ldsymbol{ldsymbol{ldsymbol{ldsymbol{eta}}}$	$oxed{oxed}$			$ldsymbol{ld}}}}}}$		$oxed{oxed}$		$oxed{oxed}$		$oxed{oxed}$	$oxed{oxed}$		$oxed{oxed}$			$oxed{oxed}$							$oxed{oxed}$	Щ				
18	Constipation																																	
19	Decreased hearing		Ш																															
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23			igsqcup																															
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

Mandle																																Reason for missed drug
Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																
Levofloxacin (Lfx)																																
Moxifloxacin (Mfx)																																
Linezolid (Lzd)																																
Pretomanid (Pmd)																																
Clofazimine (Cfz)																																
Cycloserine (Cs)																																
Delamanid (Dlm)																																
Isoniazid (Inh)																																
Rifampicin (Rif)																																
Ethambutol (Emb)																																
Pyrazinamide (Pza)																																
High Dose Isoniazid (Hh)																																
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)																																
Kanamycin (Km)																																
Amikacin (Amk)																																
Capreomycin (Cm)																																
Imipinem (Imp)	nem (Imp)																															
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes					()	Dail	ly Ok	serv	/ed																						
					1	N	Not	Sup	ervis	sed			Con	nme	nts:																	
						X	Dru	g no	t tak	en																						

	ILI DK-IB DKO			Mont				ear_																									Enter code fro	m key
_	Date:	1	2	2	1	₅	6	7	l a	۱ ۵	10	11	12	12	14	15	16	17	18	10	20	21	22	22	24	25	26	27	28	20	30	21	below Management	Outcome
-					-	J	"	_ ′		J 9	10			-5	-4	-5	10	-/	10	1-9					-4	_5				-9	30) <u> </u>	Management	Outcome
_	Side Effect																																	-
	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
_	Abdominal pain			\vdash		\vdash				\vdash				\vdash		\vdash				\vdash		\vdash		\vdash								\vdash		
_	Palpitation		\vdash	\vdash	\vdash	\vdash	+	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash		\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash				\vdash		\vdash		\vdash		
_	Diarrhea			\vdash		\vdash		\vdash	\vdash	\vdash				\vdash	\vdash	\vdash		\vdash		\vdash	\vdash	\vdash		\vdash						\vdash	\vdash	\vdash		
	Headache		\vdash	\vdash	\vdash	\vdash	+		\vdash	\vdash	\vdash		\vdash	\vdash	\vdash	\vdash	\vdash		\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash	\vdash		
_	Fatigue					\vdash	+			\vdash		\vdash						\vdash				\vdash		\vdash				<u> </u>						
_	Dizziness					\vdash	+											<u> </u>						\vdash		<u> </u>		<u> </u>						
-	Fever			\vdash		\vdash	+			\vdash				\vdash						\vdash		\vdash		\vdash										
-	Jaundice					T						İ						İ				T		İ										
11	Vision changes									T		İ				İ		İ																
12	Oedema																																	
13	Joint pain																																	
14	Rash																																	
15	Discoloration of skin and mucus membrane																																	
16	Depression																																	
17	Psychosis																																	
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade o - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																
Levofloxacin (Lfx)																																
Moxifloxacin (Mfx)																																
Linezolid (Lzd)																																
Pretomanid (Pmd)																																
Clofazimine (Cfz)																																
Cycloserine (Cs)																																
Delamanid (Dlm)																																
Isoniazid (Inh)																																
Rifampicin (Rif)																																
Ethambutol (Emb)																																
Pyrazinamide (Pza)																																
High Dose Isoniazid (Hh)																																
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)																																
Kanamycin (Km)																																
Amikacin (Amk)																																
Capreomycin (Cm)																																
Imipinem (Imp)																																
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes						0	Dail	y Ob	serv	ed_																						
						N	Not	Sup	ervis	sed			Con	nme	nts:																	
						Χ	Dru	g no	t tak	en																						

	ILI DK-IB DKO			Mont				ear_																									Enter code fro	m key
\dashv	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
\dashv	Side Effect																						l							ı				
-	Nausea —																																	
	Q-T prolongation																																	
ı	Myelosuppression																																	
- 1	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice																																	
11	Vision changes																																	
12	Oedema																																	
13	Joint pain		<u> </u>		<u> </u>	_	<u> </u>	<u> </u>	ļ		ļ		ļ				<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>		ļ	<u> </u>								<u> </u>		ļ
	Rash		<u> </u>				<u> </u>												<u> </u>					<u> </u>										
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
17	Psychosis																																	
18	Constipation		<u> </u>				_																											<u> </u>
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23			$oxed{oxed}$																															
24																																		

Side effect grading		
Grade o - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																
Levofloxacin (Lfx)																																
Moxifloxacin (Mfx)																																
Linezolid (Lzd)																																
Pretomanid (Pmd)																																
Clofazimine (Cfz)																																
Cycloserine (Cs)																																
Delamanid (Dlm)																																
Isoniazid (Inh)																																
Rifampicin (Rif)																																
Ethambutol (Emb)																																
Pyrazinamide (Pza)																																
High Dose Isoniazid (Hh)																																
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)																																
Kanamycin (Km)																																
Amikacin (Amk)																																
Capreomycin (Cm)																																
lmipinem (lmp)																																
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes					()	Dail	y Ob	serv	ed.																						
					1	٧	Not	Sup	ervis	sed			Con	nme	nts:																	
)	X	Dru	g no	t tak	en																						

	ILI DK-IB DKO			Mont				ear_																									Enter code fro	m key
\dashv	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
\dashv	Side Effect																						ļ							ı				
-	Nausea —																																	
	Q-T prolongation																																	
ı	Myelosuppression																																	
- 1	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice																																	
11	Vision changes																																	
12	Oedema																																	
13	Joint pain		<u> </u>		<u> </u>	_	<u> </u>	<u> </u>	ļ		ļ		ļ					<u> </u>	<u> </u>	<u> </u>	<u> </u>		ļ	<u> </u>								<u> </u>		ļ
	Rash		<u> </u>				<u> </u>												<u> </u>					<u> </u>										
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
17	Psychosis																																	
18	Constipation		<u> </u>				_																											<u> </u>
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23			$oxed{oxed}$																															
24																																		

Side effect grading		
Grade o - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

DAILI OBSERVA											-	_																					
Month:																																	Reason for missed drug
Date:	1	2	3	4	5	6	5 7	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																	
Levofloxacin (Lfx)																																	
Moxifloxacin (Mfx)																																	
Linezolid (Lzd)																																	
Pretomanid (Pmd)																																	
Clofazimine (Cfz)																																	
Cycloserine (Cs)																																	
Delamanid (Dlm)																																	
Isoniazid (Inh)																																	
Rifampicin (Rif)																																	
Ethambutol (Emb)																																	
Pyrazinamide (Pza)																																	
High Dose Isoniazid (Hh)																																	
Prothionamide (Pto)																																	
Ethionamide (Eto)																																	
Para-Aminosalicylic Acid (PAS)																																	
Kanamycin (Km)																																	
Amikacin (Amk)																																	
Capreomycin (Cm)																																	
Imipinem (Imp)									T		\Box																						
Amoxy-Clavulanic Acid (Amx/Clav)																																	
Mark in the boxes					I	0	Da	aily (Obs	erve	ed																			1			
						Ν	No	ot S	upe	rvise	ed			Con	nme	nts:																	
						Χ	Dr	ug i	not	take	en																						

	ILI DR-IB DRO			Mont				ear_																									Enter code fro	m key
																													-				below Management	,
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea						Π																											
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice																																	
11	Vision changes																																	
12	Oedema																																	
13	Joint pain																																	
	Rash																																	
15	Discoloration of skin and mucus membrane																																	
	Depression																																	
17	Psychosis																																	
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>					İ		T		İ				İ		İ		İ		İ		İ		T										
22			М				†	T	T	t												t		1										
23																																		
24			П			İ						İ				İ																		

Side effect grading		
Grade o - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.	December 1	2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed 4 Patient reassured	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	5 Patient hospitalized	6 Not resolved 7 Unknown

Manadha			•								•							•														Reason for missed drug
Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																
Levofloxacin (Lfx)																																
Moxifloxacin (Mfx)																																
Linezolid (Lzd)																																
Pretomanid (Pmd)																																
Clofazimine (Cfz)																																
Cycloserine (Cs)																																
Delamanid (Dlm)																																
Isoniazid (Inh)								Г																								
Rifampicin (Rif)								Г																								
Ethambutol (Emb)																																
Pyrazinamide (Pza)																																
High Dose Isoniazid (Hh)								Г																								
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)								Г																								
Kanamycin (Km)								Г																								
Amikacin (Amk)																																
Capreomycin (Cm)																																
Imipinem (Imp)																																
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes					()	Dail	y Ob	serv	/ed																						
					1	٧	Not	Sup	ervis	sed			Cor	nme	nts:																	
)	X	Dru	g no	t tak	en																						

	I DK-1D DKO			Mont				ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice												ļ																					
11	Vision changes																																	
12	Oedema		ļ						ļ	<u> </u>				_									ļ	<u> </u>										
13	Joint pain									<u> </u>																				\Box				
	Rash									_																								ļ
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
	Psychosis																																	
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade o - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.	December of	2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed 4 Patient reassured	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	5 Patient hospitalized	6 Not resolved 7 Unknown

					NO																												
Month:																																	Reason for missed drug
Date:	1	2	3	4	5	6	5 7	, 8	3	9 :	10	11	12	13	14	15	16	17	18	19	20	21	22	2 23	3 24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																	
Levofloxacin (Lfx)																																	
Moxifloxacin (Mfx)																																	
Linezolid (Lzd)																																	
Pretomanid (Pmd)																																	
Clofazimine (Cfz)																																	
Cycloserine (Cs)								T	T																								
Delamanid (Dlm)																																	
Isoniazid (Inh)																																	
Rifampicin (Rif)																																	
Ethambutol (Emb)																																	
Pyrazinamide (Pza)									T																								
High Dose Isoniazid (Hh)																																	
Prothionamide (Pto)																																	
Ethionamide (Eto)																																	
Para-Aminosalicylic Acid (PAS)																																	
Kanamycin (Km)																																	
Amikacin (Amk)									T																								
Capreomycin (Cm)																																	
Imipinem (Imp)																	ĺ																
Amoxy-Clavulanic Acid (Amx/Clav)																																	
Mark in the boxes						0	Da	ily C	bse	erve	d .																						
						Ν	No	ot Su	per	vise	ed			Con	nme	nts:																	
						X	Dr	ug n	ot ta	aker	n																						

	I DK-1D DKO			Mont				ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice												ļ																					
11	Vision changes																																	
12	Oedema		ļ						ļ	<u> </u>				_									ļ	<u> </u>										
13	Joint pain									<u> </u>																				$oxed{igspace}$				
	Rash									_																								ļ
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
	Psychosis																																	
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

DAILI OBSERVA																																
Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																
Levofloxacin (Lfx)																																
Moxifloxacin (Mfx)																																
Linezolid (Lzd)																																
Pretomanid (Pmd)																																
Clofazimine (Cfz)																																
Cycloserine (Cs)																																
Delamanid (Dlm)																																
Isoniazid (Inh)																																
Rifampicin (Rif)																																
Ethambutol (Emb)																																
Pyrazinamide (Pza)																																
High Dose Isoniazid (Hh)																																
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)																																
Kanamycin (Km)																																
Amikacin (Amk)																																
Capreomycin (Cm)																																
Imipinem (Imp)																																
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes						0	Da	ly O	oser	ved																						
						Ν	No	t Su _l	pervi	sed			Con	nme	nts:																	
						X	Dru	ıg no	ot tal	ken																						

	DAILI BICTO			Mont				ear_																									Enter code fro	m key
	Date:	_	1 .		_		1 6		١ ،	_	10		140	40		1 45	146	1 4-	40	140					24	25	26		-0			-	below Management	Outcome
		1		3	4	5	0	/	٥	9	10	11	12	13	14	15	10	1/	10	19	20	21	22	23	24	25	20	2/	20	29	30	31	Management	Outcome
	Side Effect														i				i															
	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
	Vomiting						_	_		<u> </u>					_			<u> </u>	_	<u> </u>			<u> </u>							Ш		<u> </u>		
	Abdominal pain									<u> </u>																				Ш				
	Palpitation									<u> </u>	ļ				ļ				ļ				ļ							igsquare				
5	Diarrhea		Ш																										Щ	Ш				
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice								ļ		ļ										ļ													
11	Vision changes																																	
12	Oedema							_	ļ	<u> </u>													ļ											
13	Joint pain									<u> </u>																				$oxed{igspace}$				
	Rash								<u> </u>	<u> </u>	<u> </u>		<u> </u>		<u> </u>		<u> </u>		<u> </u>				<u> </u>											
	Discoloration of skin and mucus membrane																																	
	Depression																																	
17	Psychosis																												Щ	Щ				
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	2 Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown
	_	

					NO																												
Month:																																	Reason for missed drug
Date:	1	2	3	4	5	6	5 7	, 8	3	9 :	10	11	12	13	14	15	16	17	18	19	20	21	22	2 23	3 24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																	
Levofloxacin (Lfx)																																	
Moxifloxacin (Mfx)																																	
Linezolid (Lzd)																																	
Pretomanid (Pmd)																																	
Clofazimine (Cfz)																																	
Cycloserine (Cs)								T	T																								
Delamanid (Dlm)																																	
Isoniazid (Inh)																																	
Rifampicin (Rif)																																	
Ethambutol (Emb)																																	
Pyrazinamide (Pza)									T																								
High Dose Isoniazid (Hh)																																	
Prothionamide (Pto)																																	
Ethionamide (Eto)																																	
Para-Aminosalicylic Acid (PAS)																																	
Kanamycin (Km)																																	
Amikacin (Amk)									T																								
Capreomycin (Cm)																																	
Imipinem (Imp)																	ĺ																
Amoxy-Clavulanic Acid (Amx/Clav)																																	
Mark in the boxes						0	Da	ily C	bse	erve	d .																						
						Ν	No	ot Su	per	vise	ed			Con	nme	nts:																	
						X	Dr	ug n	ot ta	aker	n																						

	ILY DR-16 DRUG	u 								110	-	17111																					1=	
			l	Mont	:h		/Y	ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	l a	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
					_			,						-5	_	-5		-,		-5				-5		-5		_,		-5	J.	<u> </u>		
	Side Effect																																-	
1	Nausea																																	
	Q-T prolongation						_	-	-	-			-						-															
	Myelosuppression																		_															
	Peripheral Neuropathy						_	_	_	_			_						_															
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue						İ	İ	İ	İ		İ	İ	İ				İ	Ì					İ									ĺ	
	Dizziness									İ		İ		İ				İ	İ	İ		İ		İ										
9	Fever																																	
10	Jaundice																																	
11	Vision changes						İ	İ	İ	İ		İ	İ	İ				İ	İ				İ	İ									ĺ	
12	Oedema					i –																												
13	Joint pain																																	
14	Rash																																	
15	Discoloration of skin and						İ	İ		İ		İ		İ				İ						İ		İ		İ					i	
	mucus membrane Depression					\vdash	T	\vdash	t	\vdash	\vdash	\vdash	t	\vdash	\vdash			\vdash	t	\vdash		\vdash		 			\vdash							
	Psychosis									İ																								
	Constipation							\vdash		T										T		\vdash		†										
	Decreased hearing						\dagger																	t									ì	
	Tinnitus		\vdash	\vdash	\vdash	\vdash	+	\vdash	+	\vdash	\vdash	\vdash	+	\vdash	\vdash	\vdash	\vdash	\vdash	+	\vdash	\vdash	\vdash	\vdash	\vdash		\vdash	\vdash	\vdash				\vdash		
	 			\vdash		\vdash		\vdash	\vdash	\vdash		\vdash	\vdash	\vdash		\vdash			\vdash	\vdash		\vdash		\vdash		\vdash		\vdash				\vdash		
21	 	_	\vdash	\vdash	\vdash		\vdash	\vdash	\vdash	\vdash	\vdash		\vdash	\vdash	\vdash	\vdash	\vdash		\vdash	\vdash	\vdash	\vdash		-	_	\vdash	\vdash	\vdash				\vdash		
	Others (lis <u>t)</u>		<u> </u>	_		_	_	_	_	_	_	_	_	_	_	_	<u> </u>	_	₩	_		_	_	<u> </u>			_					_		
22		_	 	\vdash	_	\vdash	\vdash	\vdash	_	\vdash	_	\vdash	_	_	_	_	<u> </u>	_	₩	\vdash	_	\vdash	_	_		<u> </u>	_	<u> </u>			_	<u> </u>		
23			<u> </u>	<u> </u>	<u> </u>	_	-	├	_	├	<u> </u>	 	_	_	<u> </u>	_	<u> </u>	_	 	_	\vdash	_	_				<u> </u>					_		
24	l l										$oxed{oxed}$							L						I		l							I.	

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

					NO																												
Month:																																	Reason for missed drug
Date:	1	2	3	4	5	6	5 7	, 8	3	9 :	10	11	12	13	14	15	16	17	18	19	20	21	22	2 23	3 24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																	
Levofloxacin (Lfx)																																	
Moxifloxacin (Mfx)																																	
Linezolid (Lzd)																																	
Pretomanid (Pmd)																																	
Clofazimine (Cfz)																																	
Cycloserine (Cs)								T	T																								
Delamanid (Dlm)																																	
Isoniazid (Inh)																																	
Rifampicin (Rif)																																	
Ethambutol (Emb)																																	
Pyrazinamide (Pza)									T																								
High Dose Isoniazid (Hh)																																	
Prothionamide (Pto)																																	
Ethionamide (Eto)																																	
Para-Aminosalicylic Acid (PAS)																																	
Kanamycin (Km)																																	
Amikacin (Amk)									T																								
Capreomycin (Cm)																																	
Imipinem (Imp)																	ĺ																
Amoxy-Clavulanic Acid (Amx/Clav)																																	
Mark in the boxes						0	Da	ily C	bse	erve	d .																						
						Ν	No	ot Su	per	vise	ed			Con	nme	nts:																	
						X	Dr	ug n	ot ta	aker	n																						

	I DK-1D DKO			Mont				ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice												ļ																					
11	Vision changes																																	
12	Oedema		ļ						ļ	<u> </u>				_									ļ	<u> </u>										
13	Joint pain									<u> </u>																				$oxed{igspace}$				
	Rash									_																								ļ
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
	Psychosis																																	
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	2 Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

DAILI OBSERVA											-	_																					
Month:																																	Reason for missed drug
Date:	1	2	3	4	5	6	3 7	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																	
Levofloxacin (Lfx)																																	
Moxifloxacin (Mfx)																																	
Linezolid (Lzd)																																	
Pretomanid (Pmd)																																	
Clofazimine (Cfz)																																	
Cycloserine (Cs)																																	
Delamanid (Dlm)																																	
Isoniazid (Inh)																																	
Rifampicin (Rif)																																	
Ethambutol (Emb)																																	
Pyrazinamide (Pza)																																	
High Dose Isoniazid (Hh)																																	
Prothionamide (Pto)																																	
Ethionamide (Eto)																																	
Para-Aminosalicylic Acid (PAS)																																	
Kanamycin (Km)																																	
Amikacin (Amk)																																	
Capreomycin (Cm)																																	
Imipinem (Imp)									T																								
Amoxy-Clavulanic Acid (Amx/Clav)																																	
Mark in the boxes					I	0	Da	aily (Obs	erve	ed																			1			
						Ν	No	ot S	upe	rvise	ed			Con	nme	nts:																	
						Χ	Dr	ug i	not	take	en																						

	ILI DK-IB BKO			Mont				ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
	Nausea																																	
Ť	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice																																	
11	Vision changes																																	
12	Oedema		<u> </u>			<u> </u>	<u> </u>	<u> </u>		_	<u> </u>	<u> </u>	<u> </u>	_								_		_										
13	Joint pain		<u> </u>							<u> </u>	<u> </u>	<u> </u>						<u> </u>																
14	Rash		<u> </u>							_	<u> </u>													<u> </u>										
15	Discoloration of skin and mucus membrane																																	
16	Depression		<u> </u>			<u> </u>	<u> </u>	<u> </u>		_	<u> </u>	<u> </u>	<u> </u>	_								_		_		Щ								
	Psychosis									<u> </u>																Щ								
18	Constipation		<u> </u>				ļ				<u> </u>		<u> </u>																					
19	Decreased hearing		<u> </u>								_																							
20	Tinnitus																																	
21	Tremors		$oxed{oxed}$				<u> </u>												$oxed{oxed}$							Щ								
	Others (lis <u>t)</u>																																	
22																										Щ								
23			_					_	_		_			_	_				_			_	_											
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

DAILI OBSERVA											-	_																					
Month:																																	Reason for missed drug
Date:	1	2	3	4	5	6	3 7	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																	
Levofloxacin (Lfx)																																	
Moxifloxacin (Mfx)																																	
Linezolid (Lzd)																																	
Pretomanid (Pmd)																																	
Clofazimine (Cfz)																																	
Cycloserine (Cs)																																	
Delamanid (Dlm)																																	
Isoniazid (Inh)																																	
Rifampicin (Rif)																																	
Ethambutol (Emb)																																	
Pyrazinamide (Pza)																																	
High Dose Isoniazid (Hh)																																	
Prothionamide (Pto)																																	
Ethionamide (Eto)																																	
Para-Aminosalicylic Acid (PAS)																																	
Kanamycin (Km)																																	
Amikacin (Amk)																																	
Capreomycin (Cm)																																	
Imipinem (Imp)									T																								
Amoxy-Clavulanic Acid (Amx/Clav)																																	
Mark in the boxes					I	0	Da	aily (Obs	erve	ed																			1			
						Ν	No	ot S	upe	rvise	ed			Con	nme	nts:																	
						Χ	Dr	ug i	not	take	en																						

	I DK-1D DKO			Mont				ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice																																	
11	Vision changes																																	
12	Oedema		ļ						ļ	<u> </u>				_									ļ	<u> </u>										
13	Joint pain									<u> </u>																				\Box				
	Rash									_																								ļ
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
	Psychosis																																	
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																
Levofloxacin (Lfx)																																
Moxifloxacin (Mfx)																																
Linezolid (Lzd)																																
Pretomanid (Pmd)																																
Clofazimine (Cfz)																																
Cycloserine (Cs)																																
Delamanid (Dlm)																																
Isoniazid (Inh)																																
Rifampicin (Rif)																																
Ethambutol (Emb)																																
Pyrazinamide (Pza)				L																												
High Dose Isoniazid (Hh)																																
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)			L			L																										
Kanamycin (Km)																																
Amikacin (Amk)																																
Capreomycin (Cm)																																
lmipinem (Imp)																																
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes				_	(0	Dail				-1																					
					1	N	Not	Sup	ervis	sed			Con	nme	nts:																	
)	X	Dru	g no	t tak	en																						

	DAILI BICTO			Mont				ear_																									Enter code fro	m key
	Date:	_	1 .		_		1 6				10	1 44	140	40		1 45	146	1 4-	40	140					24	25	26		-0				below Management	Outcome
		1		3	4	5	0	/	٥	9	10	11	12	13	14	15	10	1/	10	19	20	21	22	23	24	2 5	20	2/	20	29	30	31	Management	Outcome
	Side Effect								i						i				i		i													<u> </u>
	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																															_		
	Anemia																																	
	Vomiting									_		_				_		_		_			_									_		
	Abdominal pain																																	
	Palpitation										ļ				ļ				ļ		ļ													
5	Diarrhea																												Щ					
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice										ļ		ļ																					
11	Vision changes																																	
12	Oedema		ļ																													_		
13	Joint pain																																	
	Rash								<u> </u>		<u> </u>		<u> </u>		<u> </u>		<u> </u>		<u> </u>		<u> </u>													
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
17	Psychosis																												Щ					
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.	Bereitsen	2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

Month:																																	Reason for missed drug
Date:	1	2	3		4 5	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																	
Levofloxacin (Lfx)																																	
Moxifloxacin (Mfx)																																	
Linezolid (Lzd)																																	
Pretomanid (Pmd)																																	
Clofazimine (Cfz)																																	
Cycloserine (Cs)																																	
Delamanid (Dlm)																																	
Isoniazid (Inh)																																	
Rifampicin (Rif)																																	
Ethambutol (Emb)																																	
Pyrazinamide (Pza)				L																													
High Dose Isoniazid (Hh)																																	
Prothionamide (Pto)																																	
Ethionamide (Eto)																																	
Para-Aminosalicylic Acid (PAS)				L																													
Kanamycin (Km)																																	
Amikacin (Amk)																																	
Capreomycin (Cm)																																	
Imipinem (Imp)							T																										
Amoxy-Clavulanic Acid (Amx/Clav)				Γ			\dashv																										
			•																				•										
Mark in the boxes					\perp	0	[Daily	Ob:	serv	ed																						
					\perp	Ν	1	Not	Supe	ervis	ed			Con	nme	nts:																	
						Χ	[Drug	not	tak	en																						

	I DK-1D DKO			Mont				ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice																																	
11	Vision changes																																	
12	Oedema		<u> </u>						ļ	<u> </u>				_									ļ	<u> </u>										
13	Joint pain									<u> </u>																				\Box				
	Rash									_																								ļ
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
	Psychosis																																	
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																
Levofloxacin (Lfx)																																
Moxifloxacin (Mfx)																																
Linezolid (Lzd)																																
Pretomanid (Pmd)																																
Clofazimine (Cfz)																																
Cycloserine (Cs)																																
Delamanid (Dlm)																																
Isoniazid (Inh)																																
Rifampicin (Rif)																																
Ethambutol (Emb)																																
Pyrazinamide (Pza)																																
High Dose Isoniazid (Hh)																																
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)																																
Kanamycin (Km)																																
Amikacin (Amk)																																
Capreomycin (Cm)																																
lmipinem (lmp)																																
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes					()	Dail	y Ob	serv	ed.																						
					1	٧	Not	Sup	ervis	sed			Con	nme	nts:																	
)	X	Dru	g no	t tak	en																						

	I DK-1D DKO			Mont				ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice												ļ																					
11	Vision changes																																	
12	Oedema		<u> </u>						ļ	<u> </u>				_									ļ	<u> </u>										
13	Joint pain									<u> </u>																				$oxed{igspace}$				
	Rash									_																								ļ
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
	Psychosis																																	
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.	Dan walkend	2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed 4 Patient reassured	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	5 Patient hospitalized	6 Not resolved 7 Unknown

					NO																												
Month:	ļ																																Reason for missed drug
Date:	1	2	3	4	5	6	5 7	, 8	3	9 :	10	11	12	13	14	15	16	17	18	19	20	21	22	2 23	3 24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																	
Levofloxacin (Lfx)																																	
Moxifloxacin (Mfx)																																	
Linezolid (Lzd)																																	
Pretomanid (Pmd)																																	
Clofazimine (Cfz)																																	
Cycloserine (Cs)								T	T																								
Delamanid (Dlm)																																	
Isoniazid (Inh)																																	
Rifampicin (Rif)																																	
Ethambutol (Emb)																																	
Pyrazinamide (Pza)									T																								
High Dose Isoniazid (Hh)																																	
Prothionamide (Pto)																																	
Ethionamide (Eto)																																	
Para-Aminosalicylic Acid (PAS)																																	
Kanamycin (Km)																																	
Amikacin (Amk)									T																								
Capreomycin (Cm)																																	
Imipinem (Imp)																	ĺ																
Amoxy-Clavulanic Acid (Amx/Clav)																																	
Mark in the boxes						0	Da	ily C	bse	erve	d .																						
						N	No	ot Su	per	vise	ed			Con	nme	nts:																	
						X	Dr	ug n	ot ta	aker	n																						

	I DK-1D DKO			Mont				ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice																																	
11	Vision changes																																	
12	Oedema		<u> </u>						ļ	<u> </u>				_									ļ	<u> </u>										
13	Joint pain									<u> </u>																				$oxed{igspace}$				
	Rash									_																								ļ
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
	Psychosis																																	
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.	December of	2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed 4 Patient reassured	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	5 Patient hospitalized	6 Not resolved 7 Unknown

Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	1	8		10	11	12	13	14	15	16	17	18	10	20	21	22	23	24	25	26	27	28	20	20	31	
Bedaquiline (Bdq)			3	4	3		<i>'</i>		9		11	12	13	14	12	10	1/	10	19	20		22	23	-4	25	20	۷/	20	-29	30	21	
Levofloxacin (Lfx)								\vdash														\vdash	\dashv		\dashv	\dashv						
Moxifloxacin (Mfx)								\vdash		\vdash								\vdash				\vdash	\dashv		\dashv	\dashv						
Linezolid (Lzd)		_						\vdash											_	-		\vdash			_	\dashv		_				
Pretomanid (Pmd)																									_							
Clofazimine (Cfz)																						-			_	\dashv						
Cycloserine (Cs)						H													_			\square			_	\dashv		_			_	
Delamanid (Dlm)								_		-																\dashv						
soniazid (Inh)								<u> </u>		_										\blacksquare		Н			_	\dashv	-					
Rifampicin (Rif)																										4						
Ethambutol (Emb)																										_						
Pyrazinamide (Pza)																						Щ				\Box						
High Dose Isoniazid (Hh)																																
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)																																
Kanamycin (Km)																																
Amikacin (Amk)																									\neg	\sqcap						
Capreomycin (Cm)																									\neg							
lmipinem (Imp)																									\dashv	\neg						
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes					()	Dail	y Ob	serv	ed								-														
					١	1	Not	Sup	ervis	sed			Con	nme	nts:																	
					,	<	Dru	a no	t tak	en																						

	ILI DK-IB DKO			Mont				ear_																									Enter code fro	m kov
																																	below	-
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice																																	<u> </u>
11	Vision changes																																	
12	Oedema							<u> </u>		┞	<u> </u>	<u> </u>												Щ		Ш								Ļ
13	Joint pain					_			<u> </u>	_	<u> </u>	<u> </u>												Щ										
14	Rash									_	<u> </u>											Ш		Щ										ļ
15	Discoloration of skin and mucus membrane																																	
16	Depression																							Ш										
17	Psychosis									$oxed{oxed}$												Щ		Щ										
18	Constipation				<u> </u>		<u> </u>				<u> </u>		<u> </u>						<u> </u>					Щ										
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade 0 - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.		2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

Month:																																	Reason for missed drug
Date:	1	2	3		4 5	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																	
Levofloxacin (Lfx)																																	
Moxifloxacin (Mfx)																																	
Linezolid (Lzd)																																	
Pretomanid (Pmd)																																	
Clofazimine (Cfz)																																	
Cycloserine (Cs)																																	
Delamanid (Dlm)																																	
Isoniazid (Inh)																																	
Rifampicin (Rif)																																	
Ethambutol (Emb)																																	
Pyrazinamide (Pza)				L																													
High Dose Isoniazid (Hh)																																	
Prothionamide (Pto)																																	
Ethionamide (Eto)																																	
Para-Aminosalicylic Acid (PAS)				L																													
Kanamycin (Km)																																	
Amikacin (Amk)																																	
Capreomycin (Cm)																																	
Imipinem (Imp)							T																										
Amoxy-Clavulanic Acid (Amx/Clav)				Γ			\dashv																										
			•																				•										
Mark in the boxes					\perp	0	[Daily	Ob:	serv	ed																						
					\perp	Ν	1	Not	Supe	ervis	ed			Con	nme	nts:																	
						Χ	[[Drug	not	tak	en																						

	I DK-1D DKO			Mont				ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
1	Nausea																																	
	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice												ļ																					
11	Vision changes																																	
12	Oedema		<u> </u>						ļ	<u> </u>				_									ļ	<u> </u>										
13	Joint pain									<u> </u>																				\Box				
	Rash									_																								ļ
	Discoloration of skin and mucus membrane																																	
16	Depression																																	
	Psychosis																																	
18	Constipation																																	
19	Decreased hearing																																	
20	Tinnitus																																	
21	Tremors																																	
	Others (lis <u>t)</u>																																	
22																																		
23																																		
24																																		

Side effect grading		
Grade o - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.	Dans well-word	2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed 4 Patient reassured	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	5 Patient hospitalized	6 Not resolved 7 Unknown

DAILI OBSERVA																																
Month:																																Reason for missed drug
Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Bedaquiline (Bdq)																																
Levofloxacin (Lfx)																																
Moxifloxacin (Mfx)																																
Linezolid (Lzd)																																
Pretomanid (Pmd)																																
Clofazimine (Cfz)																																
Cycloserine (Cs)																																
Delamanid (Dlm)																																
Isoniazid (Inh)																																
Rifampicin (Rif)																																
Ethambutol (Emb)																																
Pyrazinamide (Pza)																																
High Dose Isoniazid (Hh)																																
Prothionamide (Pto)																																
Ethionamide (Eto)																																
Para-Aminosalicylic Acid (PAS)																																
Kanamycin (Km)																																
Amikacin (Amk)																																
Capreomycin (Cm)																																
Imipinem (Imp)																																
Amoxy-Clavulanic Acid (Amx/Clav)																																
Mark in the boxes						0	Da	ly O	oser	ved																						
						Ν	No	t Su _l	pervi	sed			Con	nme	nts:																	
						X	Dru	ıg no	ot tal	ken																						

	ILI DK-IB BKO			Mont				ear_																									Enter code fro	m key
	Date:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	below Management	Outcome
	Side Effect																																	
	Nausea																																	
Ť	Q-T prolongation																																	
	Myelosuppression																																	
	Peripheral Neuropathy																																	
	Anemia																																	
2	Vomiting																																	
3	Abdominal pain																																	
4	Palpitation																																	
5	Diarrhea																																	
6	Headache																																	
7	Fatigue																																	
8	Dizziness																																	
9	Fever																																	
10	Jaundice																																	
11	Vision changes																																	
12	Oedema		<u> </u>			<u> </u>	<u> </u>	<u> </u>		_	<u> </u>	<u> </u>	<u> </u>	_								_												
13	Joint pain		<u> </u>							<u> </u>	<u> </u>	<u> </u>																						
14	Rash		<u> </u>							_	<u> </u>													<u> </u>										
15	Discoloration of skin and mucus membrane																																	
16	Depression		<u> </u>			<u> </u>	<u> </u>	<u> </u>		_	<u> </u>	<u> </u>	<u> </u>	_								_		_		Щ								
	Psychosis						<u> </u>			<u> </u>																Щ								
18	Constipation		<u> </u>				ļ				<u> </u>		<u> </u>																					
19	Decreased hearing		<u> </u>								_																							
20	Tinnitus																																	
21	Tremors		$oxed{oxed}$				<u> </u>												$oxed{oxed}$							Щ								
	Others (lis <u>t)</u>																																	
22																										Щ								
23			_						_		_			_	_				_			_	_											
24																																		

Side effect grading		
Grade o - No side effect.	1 Drug withdrawn	1 Recovering/Resolving
Grade 1 - Mild symptoms that don't interrupt normal functioning but requiring reassurance.	December	2 Recovered/Resolved
Grade 2 - Moderate symptoms causing greater than some interference in normal functioning. Requires monitoring and reassurance.	₂ Dose reduced	3 Requires prolonged hospitalization
Grade 3 - Severe symptoms causing limitation in normal functioning. Requires clinical intervention including regimen modification.	3 Dose not changed	4 Causes congenital anomaly 5 Permanent disability/morbidity
Grade 4 - Potentially life threatening symptoms causing inability to perform. Requires hospitalization for management.	4 Patient reassured 5 Patient hospitalized	6 Not resolved 7 Unknown

10. MONITORING FOR QUALITY OF CARE

10.1. Sputum Monitoring and Follow Up

Month No.	Date	Serial No.	Test result				Comment(s) / Action
		Serial No.	Smear Microsco (Tick appropriate	ppy ely)	Culture (Tick appropriat	ely)	
			Positive	Negative	Growth	No Growth	
Baseline							
1.							
2.							
3.							
4.							
5.							
6.							
7.							
8.							
9.							
10.							
11.							
12.							
13.							
14.							
15.							
16.							
17.							
18.							

10.2. Laboratory and Clinical Follow Up

RESULTS

			Full hea	mogram					Serum				CD4	Vival		Pregnancy	FCG (GT	Visual		
	TESTS:	RBC	WBC	Platelets	НВ	Bilirubin	AST	ALT	Albumin	Creatinine	Magnesium	Potassium	CD4 Count	Viral load	TSH	Pregnancy test	interval)	test	RBS	Other (specify)
Month of Treatment	Date																			
Baseline (Month 0)																				
									-											
		 								<u> </u> 										
	İ																			
									ļ											

10.3. Monitoring Schedule for Patients on Injectable Free Regimen

	Baseline	1	2	3	4	5	6	7	8	9	10	11	12	15	18
atient Counselling	х	X	х	х	х										
creening for substance buse	×				x										
eview by a Clinician	х	Every 2 weeks						Monthly unt	il treatmen	t completio	n				
DR screening	X						Monti	nly until trea	tment com	pletion					
Veight/BMI/Z-Score	X						Monti	nly until trea	tment com	pletion					
mear microscopy	X						Monti	nly until trea	stment com	pletion					
ulture	X						Monti	nly until trea	tment com	pletion					
it line DST	X			X (If s	till smear po	sitive)		X	If any rever	rsion to posit	tive culture	in the conti	nuation pha	ise)	
ine DST	X			X (If s	till smear po	sitive)		X	(If any rever	rsion to posit	tive culture	in the conti	nuation pha	ise)	
LT/ AST/ Bilirubin	X				Repeat it	patient is	omiting, ha	s abdomina	pain, jauno	fice or any e	vidence of I	iver injury			
erum Albumin	X						1 1 1 1			1 1 1				1 1 1	
reatinine	X		Do	monthly if	on an inject	able drug. 0	therwise re	peat only if	the baselin	e creatinine	was abnorr	nal or if clin	ically indicat	ted.	
otassium, Magnesium	Х		D	o monthly if	on an inject	table drug.	Otherwise n	epeat if yon	iting, diarri	hoea, if QTc	F is prolonge	ed or if clink	cally indicate	ed.	
il Hemogram	X	X	X	X	X	Х	X				Monthly if	on Linezolid			
IV Test	X							As per HTS	guidelines						
D4	X*							As per AR1	guidelines						
iral Load	X*							As per ART	guidelines						
85	X					LLL	LLL	LLLL			LLL			1.1.1	X
0.0	$\overline{}$	144	w	X	X	Х	Х	X	X	X	X	X	X	X	X
	X	X	A												
eview Contraception	X	X	Α												
eview Contraception regnancy Test	X X	X	A												X
eview Contraception regnancy Test XR	X X X	X	x	111							111				X
regnancy Test XR SH	X X X X	X	X							1 1 1	1 1 1				X
teview Contraception regnancy Test XR SH audiometry‡ CG (QTcF monitoring)††	X X X X X	Every 2 weeks	x	x	x	x	х			x	1 1 1		х	x	x

10.4. DR TB Treatment Adjustment

Drug	Treatment Start date	Initial Dos- age	Date of Dose adjustment	Adjusted Dose	Reason for adjusting dosage	Date drug substitut- ed	Reason for drug substitution
Bedaquiline (Bdq)							
Levofloxacin (Lfx)							
Pretomanid (Pmd)							
Moxifloxacin (Mfx)							
Linezolid (Lzd)							
Clofazimine (Cfz)							
Cycloserine (Cs)							
Delamanid (Dlm)							
Isoniazid (Inh)							
Rifampicin (Rif)							
Ethambutol (Emb)							
Pyrazinamide (Pza)							
High Dose Isoniazid (Hh)							
Prothionamide (Pto)							
Ethionamide (Eto)							
Para-Aminosalicylic Acid (PAS)							
Kanamycin (Km)							
Amikacin (Amk)							
Capreomycin (Cm)							
Imipinem (Imp)							
Amoxy-Clavulanic Acid (Amx/Clav)							

10.5. Nutritional Intervention

Nutrition support	Code
Nutritional Counselling	NC
Therapeutic feeds	RUTF
Supplementary Feeds	FBF
Vitamin A	
Pyridoxine	
Not Done	ND

11. CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLI	NICAL NOTES	

CLINICAL NOTES	CLI	NICAL NOTES	

CLINICAL NOTES	CLINICAL NOTES

CLINICAL NOTES	CLINICAL NOTES

12. MONTHLY DR TB CLINICAL REVIEW TEAM CHECKLIST

- To be filled by the chair of the review team
 Confirm and put a tick against each variable carried out

		Base line	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
1	Date																									
2	Record age in years																									
3	Record weight at current visit																									
4	Record BMI at current visit																									
5	Nutrition support given Y/N																									
6	Record follow up tests reviewed at visit depending on month of treatment (au- diometry, hgm, LFTs, UECs, CXR, LFTs, CD4, repeat																									
7	Blood drawn for Lancet Labs Y/N																									
8	Screen for clinical symptoms of common ADRs (and complete the daily DR TB side effect monitoring form)																									
9	ADR forms filled and reported to county pharmacist Y/N																									
10	Drug adjustments made Y/N																									
11	Record reasons for drug adjust- ment e.g. weight gain, weight loss, ADR																									
12	Record date drugs adjusted																									
13	Record results of latest monthly smear microscopy																									
14	Record results of latest monthly culture																									
15	Where applicable, any ART adjustments made to dosage? Y/N																									
16	Record date adjustment made																									
17	Record reason for ART adjustments e.g. ADR, ART Resistance																									
18	Patients received monthly support Y/N																									
19	Has the patient been enrolled with NHIF																									
20	Where applicable DOTS nurse received monthly transport support Y/N																									
21	DR TB Tx Counselling done? Y/N																									

Outcome	Mark One	Date of Outcome
Cured		
Treatment Complete		
Treatment Failed		
Lost to Follow Up		
Transferred Out Not outcome (consider deleting)		
Died		

14. POST DR-TB TREATMENT FOLLOW UP
Patients will be followed up for a period of 2 years after treatment completion to assess for any relapses/re-infection and post TB treatment complications that may arise.

Refer to table below for guidance

		1	1		1		
Post TB treatment follow up							
Patients will be followed up for a period of 2 years table below for guidance	after treatment completion to assess for any relapses	s/re-infection and post TB treatme	ent complic	ations that	t may arise. Refer to		
Indicate Month (after treatment completion)		3	6	12	18	24	Remarks
Review by clinician(evaluate for symptoms including TB and other lung conditions and record at every visit)							
Weight/BMI (Done at each follow up visit)							
Screening for substance abuse (type findings)							
Imaging: CXR , CT scan (Done for any presumptive Post TB Lung Disease patient (PTLD) on follow up)							
Diagnostic tests t	for Presumtive TB						
TEST	TEST RESULT (indicate date)						
XPERT MTB/RIF/ ULTRA							
TRUENAT							
LPA (1st & 2nd Line)							
Culture & DST,1st & 2nd Line							
Spirometry (Done as clinically indicated (When there is impairement of lung function)							
Diagnosis (See Key below for options of diagnosis)							
1. Tuberculosis 2. Asthma 3. Lung scarring (fibrosis) 4. Bronchiectasis 5. Chronic Obstructive Pulmonary Disease (COPD) 6. Lung abscess 7. Aspergillus-related lung disease 8. Spontaneous Pneumothorax 9. Interstitial lung diseases 10. Lung cancer 11. Other specify							



National Tuberculosis, Leprosy and Lung Disease Program
1st Floor, Afya Annex, Kenyatta National Hospital Grounds
P.O. Box 20781 – 00202 Nairobi
Email: info@nltp.co.ke
www.nltp.co.ke







